Aclarion Gains Financial Support to Study its Low Back Pain Locator Tech

Aclarion Inc. has secured $20 million to fully fund a trial to assess the company’s solution for pinpointing lower back pain.

The company raised the funds in a little more than a month (since Jan. 1). The CLARITY trial is a prospective, randomized, multicenter, study to validate Nociscan’s ability to improve surgical outcomes for chronic low back pain patients. Enrolling 300 patients across multiple sites, it builds on peer-reviewed data demonstrating Nociscan’s potential to drive better surgical outcomes by matching the surgical intervention to the affected discs. The study will be led by Dr. Nicholas Theodore of Johns Hopkins.

“This milestone ensures we reach the study’s conclusion, potentially unlocking broad payer coverage and redefining chronic low back pain treatment,” Aclarion Chief Strategy Officer Ryan Bond stated.

Chronic low back pain is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported Software-as-a-Service (SaaS) platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.

Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from a magnetic resonance imaging machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.

When used with other diagnostic tools, Nociscan demonstrates a 97% surgical success rate at one year follow up when all Nociscan-identified pain positive discs are treated.

Aclarion leverages MRS proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The company is based in Broomfield, Colo.